{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(7)"],"submitter":["Xu X"],"pubmed_abstract":["Chimeric antigen receptor T cells are T cells genetically engineered with CAR constructs which mainly contain scFV and TCR zeta chain. With promising development in blood cancers, CAR T trials are also applied in solid cancers. However, the treatment effect in solid cancers is lower than expected. This review summarizes difference of CAR T applications in solid and blood cancers. Future challenges of CAR T cell treatment in solid cancer are also discussed using ovarian cancer as an example."],"journal":["Human vaccines & immunotherapeutics"],"pagination":["1548-1555"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5512759"],"repository":["biostudies-literature"],"pubmed_title":["The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model."],"pmcid":["PMC5512759"],"pubmed_authors":["Qiu J","Xu X","Sun Y"],"additional_accession":[]},"is_claimable":false,"name":"The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.","description":"Chimeric antigen receptor T cells are T cells genetically engineered with CAR constructs which mainly contain scFV and TCR zeta chain. With promising development in blood cancers, CAR T trials are also applied in solid cancers. However, the treatment effect in solid cancers is lower than expected. This review summarizes difference of CAR T applications in solid and blood cancers. Future challenges of CAR T cell treatment in solid cancer are also discussed using ovarian cancer as an example.","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jul","modification":"2025-04-19T18:42:55.275Z","creation":"2019-03-26T23:06:43Z"},"accession":"S-EPMC5512759","cross_references":{"pubmed":["28272967"],"doi":["10.1080/21645515.2017.1291473"]}}